One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Axon Enterprise logo
Axon Enterprise AXON
$ 379.58 -10.58%
report update icon

Quarterly report 2026-Q1
added 05-16-2026

Axon Enterprise Financial Statements 2025-2008 | AXON

Annual Financial Statements Axon Enterprise

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

30.6 B 39.8 B 20.2 B 14.2 B 9.28 B 10.2 B 4.64 B 2.8 B - - 824 M 1.43 B 846 M 449 M 278 M 258 M 282 M -

Shares

78.1 M 75.7 M 74.2 M 71.1 M 66.2 M 61.8 M 59.2 M 56.4 M - - 53.5 M 52.9 M 51.9 M 53.8 M 59.4 M 62.5 M 61.9 M -

Historical Prices

392 526 272 200 140 165 77.4 53.8 34.8 25.7 19.4 23.5 19.2 7.47 4.03 4.13 4.56 7.06

Net Income

125 M 377 M 176 M 147 M -60 M -1.72 M 882 K 29.2 M 5.21 M 17.3 M 19.9 M 19.9 M 18.2 M 14.7 M -7.04 M -4.38 M -1.11 K -

Revenue

2.78 B 2.08 B 1.56 B 1.19 B 863 M 681 M 531 M 420 M 344 M 268 M 198 M 165 M 138 M 115 M 90 M - - -

Cost of Revenue

1.12 B 841 M 605 M 461 M 322 M 265 M 224 M 161 M 137 M 97.7 M 69.2 M 63 M 52 M 47 M 41.8 M - - -

Gross Profit

1.66 B 1.24 B 955 M 726 M 541 M 416 M 307 M 259 M 207 M 171 M 129 M 102 M 85.8 M 67.7 M 44.5 M 45.4 M 63.4 M -

Operating Income

-62.1 M 58.5 M 157 M 93 M -168 M -14.2 M -6.39 M 24.8 M 13 M 31.9 M 35.3 M 32.5 M 27.9 M 22.5 M -10.9 M -5.14 M -79.2 K -

Interest Expense

99.9 M 286 M -41.9 M 99 M 25.3 M - - - - - - - - - - - - -

EBITDA

21.1 M 107 M 176 M 116 M -149 M -1.68 M -655 K 30.9 M 21.1 M 35.5 M 37.2 M 33.8 M 30.6 M 27 M 1.33 M 2.15 M 3.56 M -

Operating Expenses

1.72 B 1.18 B 799 M 633 M 709 M 430 M 314 M 234 M 194 M 139 M 93.3 M 69 M 56.5 M 47.2 M 51.3 M 50.5 M 63.5 M -

General and Administrative Expenses

1.04 B 741 M 495 M 399 M 515 M 307 M 178 M 131 M 121 M 92.9 M 57.1 M 44.8 M 39.3 M - 41.3 M 39 M 43.5 M -

All numbers in USD currency

Quarterly Income Statement Axon Enterprise

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

80.2 M 78.4 M 78 M 76.9 M 76.6 M 75.7 M 75.5 M 75.4 M 74.8 M 74.2 M 72.6 M 71.5 M 71.1 M 71 M 71 M 70.9 M 66.2 M 65.2 M 64 M 63.8 M 63.5 M 60.3 M 59.6 M 59.5 M 59.3 M 59.2 M 58.9 M 58.8 M 58.3 M 55.5 M 53.1 M 53 M 52.8 M 52.7 M 52.4 M 52.3 M 52.2 M 52.5 M 53.7 M 53.7 M 53.7 M 53.6 M 53.2 M 53 M 52.5 M 53.4 M 53.2 M 52.7 M 51.3 M 51.1 M 52.7 M 52.8 M 52.5 M 54.5 M 55.7 M 55.7 M 58.8 M 60.6 M 62.4 M

Net Income

169 M -2.19 M 36.1 M 88 M - 67 M 40.8 M 133 M 59.4 M 12.4 M 45.1 M - 12.1 M 51 M 54.9 M - 48.5 M -47.1 M -47.9 M - -873 K -30.8 M 4.07 M -12.4 M 6.1 M 738 K 6.42 M 2.08 M 5.71 M 8.48 M 12.9 M 5.21 M 422 K 2.28 M 4.58 M 6.34 M 3.84 M 3.65 M 3.46 M 5.1 M 1.52 M 6.1 M 7.2 M 5.09 M 7.56 M 3.88 M 3.39 M 5.38 M 5.11 M 4.46 M 3.3 M 3.82 M 3.68 M 3.44 M 3.8 M -5.9 M 1.14 M -2.29 M 19.7 K

Revenue

807 M 711 M 669 M 604 M - 544 M 504 M 460 M 414 M 375 M 343 M - 312 M 286 M 256 M - 232 M 219 M 195 M - 166 M 141 M 147 M 172 M 131 M 112 M 116 M 115 M 105 M 99.2 M 101 M 94.7 M 90.3 M 79.6 M 79.2 M 82.1 M 71.9 M 58.8 M 55.5 M - 50.4 M 46.7 M 44.8 M - 44.3 M 37.2 M 36.2 M - 35.2 M 32.2 M 30.4 M - 28.8 M 28.2 M 25.6 M - 24.4 M 21.2 M -

Cost of Revenue

330 M 283 M 265 M 238 M - 214 M 200 M 201 M 158 M 142 M 139 M - 118 M 112 M 101 M - 87.4 M 80.9 M 71.7 M - 68.2 M 53.1 M 58.6 M - 50.7 M 46.8 M 46.9 M - 39.2 M 36.1 M 36.8 M - 40.5 M 34 M 30.6 M - 25.3 M 21.5 M 18.6 M - 19.3 M 16 M 14.9 M - 15.6 M 14 M 14 M - 13.1 M 12.4 M 12 M - 12 M 11.7 M 10.4 M - - - -

Gross Profit

477 M 427 M 404 M 366 M - 331 M 304 M 259 M 255 M 232 M 204 M - 193 M 174 M 156 M - 145 M 138 M 123 M - 98.2 M 88.2 M 88.6 M 92.6 M 80.2 M 65.6 M 68.9 M 65.3 M 65.6 M 63.1 M 64.5 M 63 M 49.8 M 45.6 M 48.7 M 49.8 M 46.6 M 37.3 M 36.9 M 37 M 31.1 M 30.7 M 29.9 M 27.4 M 28.7 M 23.2 M 22.2 M 25.6 M 22.1 M 19.7 M 18.5 M 19.2 M 16.8 M 16.5 M 15.2 M 6.98 M 13.1 M 12.2 M 12.2 M

Operating Income

29.2 M -2.13 M -1.04 M -8.79 M - 24.1 M 32.9 M 16.5 M 55.1 M 40.3 M 16.6 M - 32.1 M 21.4 M 17.2 M - 2.89 M -93.7 M -50.3 M - -5.45 M -13.7 M -800 K - 6.62 M -1.3 M 2.67 M - 3.97 M 5.3 M 13.6 M - -799 K 824 K 5.35 M - 11.1 M 6.21 M 5.14 M - 6.71 M 9.37 M 10.7 M - 12.5 M 6.21 M 4.86 M - 6.88 M 6.81 M 5.26 M - 5.28 M 6.06 M 6.46 M - 1.21 M -5.02 M 110 K

Interest Expense

189 M 22.8 M -32.4 M 114 M - 44.5 M 7.93 M 139 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

59.6 M 54.1 M 35.6 M 10.7 M - 54.8 M 57.4 M 23.8 M - - 23.3 M - 32.1 M 33.4 M 22.9 M - 2.89 M -85.1 M -46 M - 3.5 M -7.86 M 2.08 M - 14.8 M 4.19 M 5.47 M - 12.2 M 10.5 M 16 M - 1.48 M 2.62 M 6.95 M - 12 M 7.15 M 6.04 M - 7.65 M 10.1 M 11.4 M - 13.6 M 7.32 M 6.02 M - 7.97 M 8.34 M 6.68 M - 7 M 7.79 M 8.12 M - 3.21 M -2.82 M 2.18 M

Operating Expenses

448 M 429 M 405 M 375 M - 307 M 271 M 242 M 200 M 192 M 187 M - 161 M 153 M 139 M - 142 M 232 M 174 M - 104 M 102 M 89.4 M - 73.6 M 66.9 M 66.2 M - 61.7 M 57.8 M 50.9 M - 50.6 M 44.8 M 43.3 M - 35.5 M 31.1 M 31.8 M - 24.4 M 21.3 M 19.1 M - 16.2 M 17 M 17.4 M - - - - - - - - - - - -

General and Administrative Expenses

259 M 253 M 242 M 224 M - 192 M 169 M 151 M 123 M 120 M 117 M - 102 M 95 M 90.1 M - 99.3 M 178 M 127 M - 74.4 M 72.3 M 63 M - 48.4 M 43.4 M 42.9 M - 39.7 M 39.3 M 35.8 M - 36.4 M 31.8 M 30.9 M - 28.1 M 24.4 M 24.8 M - 17.8 M 15.4 M 14.6 M - 12.4 M 13.5 M 13.7 M - 12.8 M 10.9 M 11.2 M - 9.54 M 8.4 M 8.85 M - 9.48 M 9.07 M 9.35 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Axon Enterprise AXON
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Axon Enterprise plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.55 -12.99 % $ 273 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.34 -5.32 % $ 141 M niderlandNiderland
Ocular Therapeutix Ocular Therapeutix
OCUL
$ 6.48 -9.31 % $ 1.21 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 5.8 -0.34 % $ 94.8 M israelIsrael
Summit Therapeutics Summit Therapeutics
SMMT
$ 14.17 -12.37 % $ 10.6 B britainBritain
Outlook Therapeutics Outlook Therapeutics
OTLK
$ 0.44 -4.63 % $ 15.3 M usaUSA
uniQure N.V. uniQure N.V.
QURE
$ 20.96 -9.01 % $ 1.21 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
$ 15.55 -9.38 % $ 1.53 B usaUSA
Rafael Holdings Rafael Holdings
RFL
$ 1.06 -4.5 % $ 54.5 M usaUSA
REGENXBIO REGENXBIO
RGNX
$ 7.37 -4.47 % $ 380 M usaUSA
Sanofi Sanofi
SNY
$ 46.87 -1.26 % $ 57.2 B franceFrance
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 45.56 -11.17 % $ 819 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.65 -8.84 % $ 64.7 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 45.27 -1.78 % $ 5.19 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Rezolute Rezolute
RZLT
$ 3.65 -7.95 % $ 379 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 0.62 -2.71 % $ 66.1 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 1.72 1.04 % $ 1.16 B israelIsrael
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Seer Seer
SEER
$ 1.63 -4.12 % $ 90.3 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 12.8 -8.47 % $ 1.72 B usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 19.73 -0.35 % $ 2.8 B britainBritain
Soligenix Soligenix
SNGX
$ 0.33 -5.02 % $ 1.71 M usaUSA
Spruce Biosciences Spruce Biosciences
SPRB
$ 42.5 -8.82 % $ 32.6 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 26.77 -5.1 % $ 1.51 B usaUSA
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Savara Savara
SVRA
$ 4.33 -7.06 % $ 963 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 167.62 -3.93 % $ 209 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
$ 58.02 -5.86 % $ 8.37 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 11.01 -6.5 % $ 1.53 B usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.17 -10.2 % $ 6.47 M usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 3.6 -7.22 % $ 212 M usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
- -6.00 % $ 238 M usaUSA